Certified by Founder
Lodge
NeuroSense Therapeutics
start up
United States
- Cambridge, Massachusetts
- 09/12/2021
- Unknown
- $12,000,000
Advancing research, development and therapy for ALS and additional CNS indications.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical stage Biotech company focusing on the development of a ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases.
Currently in preparations towards a Phase IIb in ALS patients in USA and Israel.
- Industry Biotechnology Research
- Website http://www.neurosense-tx.com/
- LinkedIn https://www.linkedin.com/company/neurosense-therapeutics/about/
Related People
Alon Ben-NoonCo Founder
Israel -
Herzliyya, Tel Aviv
Life Sciences Executive ; Leading NeuroSense Therapeutics, a Biotech startup which accelerates research, development and therapy for ALS (Amyotrophic Lateral Sclerosis) and additional Neurodegenerative diseases.
LinkedIn
https://www.linkedin.com/in/alonbn/
Leona Health | $14,000,000 | (Dec 18, 2025)
Limenet | $8,217,860 | (Dec 18, 2025)
Codoxo | $35,000,000 | (Dec 18, 2025)
Drive Health | $15,000,000 | (Dec 18, 2025)
DataLane | $22,500,000 | (Dec 18, 2025)
Addition Therapeutics | $100,000,000 | (Dec 18, 2025)
T-CURX GmbH | $20,000,000 | (Dec 18, 2025)
Scylos | $3,000,000 | (Dec 18, 2025)
Last Energy | $100,000,000 | (Dec 18, 2025)
Navier AI | $6,500,000 | (Dec 17, 2025)
Verisoul | $8,800,000 | (Dec 17, 2025)
Aeovian Pharmaceuticals | $55,000,000 | (Dec 17, 2025)